Premium
Chemoprophylaxis and immunity to parasitic bronchitis in cattle — a field experiment comparing topical ivermectin and an oxfendazole intraruminal device
Author(s) -
JACOBS D. E.,
FOX M. T.,
PILKINGTON J. G.,
ROSS D. B.,
RYAN W. G.
Publication year - 1989
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1989.tb00696.x
Subject(s) - lungworm , ivermectin , oxfendazole , anthelmintic , veterinary medicine , feces , deworming , biology , veterinary parasitology , pneumonia , zoology , nematode , helminths , physiology , medicine , immunology , fenbendazole , microbiology and biotechnology , ecology
Seeder calves infected with Dictyocaulus viviparus were used to contaminate a Field divided into three similar paddocks. Twenty‐four autumn‐born calves were allocated to three matched groups; one group was given topical ivermectin treatments (0.5 mg/kg) at 3, 8 and 13 weeks after turnout (Day 0); each member of a second group was given an oxfendazole pulse‐release intraruminal device (OPRB) at turnout; while a third group was kept as untreated controls to monitor the natural epidemiological pattern of events. Severe pasteurella pneumonia exacerbated by lungworm infection occurred in the controls after Day 24. Two died and repeated doses of antibiotic and anthelmintic therapy were necessary to save the remainder. Clinical signs were much milder in the ivermectin and OPRB groups and resolved with only a single dose of antibiotic. The OPRB group excreted some lungworm larvae at this time, but none was detected in the faeces of the ivermectin group during the grazing season. At housing, five calves from each group and four lungworm‐naive calves were challenged with D. viviparus larvae. The infection became patent in all challenge‐control calves, but no larvae were passed by any of the trial animals. Post‐mortem worm‐counts revealed percentage takes for the challenge controls, trial controls, ivermectin and OPRB groups of 16.7, 0.01, 0.9 and 0.2, respectively. All trial groups had therefore developed a substantial immunity.